Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Sep 13, 2018

(R) Cantargia has been approved for listing on the main market of Nasdaq Stockholm

Aug 21, 2018

(R) Cantargia publishes half year report

Aug 13, 2018

(R) Cantargia presents update on the CANFOUR clinical trial and phase IIa preparations

Aug 1, 2018

(R) Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in China

Jul 13, 2018

(R) Cantargia approved for listing on Nasdaq Stockholm First North Premier as part of the process towards Nasdaq Stockholm's main market

Jul 11, 2018

(R) Cantargia receives Intention to grant notification from EPO for expanded patent protection in treatment of solid tumours

Jun 26, 2018

(R) Cantargia announces pre-clinical results showing positive effects of CAN04 combined with approved cancer therapies

Jun 26, 2018

(R) Cantargia obtains two new granted patents in USA for antibody based cancer therapy against IL1RAP

Jun 19, 2018

(R) Cantargia’s immuno-oncology antibody CAN04 has obtained the INN nidanilimab by WHO

Jun 1, 2018

(R) Annual General Meeting in Cantargia AB (publ)

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye